Adelaide Research & Scholarship
Statistics
Total Visits
| Views | |
|---|---|
| Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial(legacy) | 140 |
| Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial(legacy) | 84 |
Total Visits per Month
| October 2023 | November 2023 | December 2023 | January 2024 | February 2024 | March 2024 | April 2024 | |
|---|---|---|---|---|---|---|---|
| Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial | 0 | 6 | 2 | 4 | 0 | 5 | 4 |
File Downloads
| Views |
|---|
Top Country Views
| Views | |
|---|---|
| United States | 64 |
| China | 22 |
| France | 14 |
| Netherlands | 8 |
| Vietnam | 6 |
| Australia | 2 |
| Ireland | 2 |
| Switzerland | 1 |
| United Kingdom | 1 |
| India | 1 |
Top City Views
| Views | |
|---|---|
| Ashburn | 22 |
| Fairfield | 8 |
| Rotterdam | 8 |
| Hanoi | 6 |
| Beijing | 5 |
| Cambridge | 3 |
| New York | 3 |
| San Ramon | 3 |
| Boardman | 2 |
| Brisbane | 2 |